Related sites
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

الصحة النفسية: دعوة للشراكة مع المؤسسات العامة والأكاديميا ومنظمات المجتمع المدني


The Ministry of Public Health’s Vision is that of “An equitable health system that identifies and addresses the key determinants of physical and mental health and promotes, develops and sustains the highest attainable physical and mental health status of all Lebanese.”
 
To achieve this vision, the Ministry aims at building and sustaining an effective, high impact organization and works in partnership with all stakeholders, following good governance principles, to develop its institutional capacity for effective stewardship of the health sector, to ensure the promotion of better health and the provision of equitable, efficient and quality health services, in both public and private sector, that respond to people’s needs, with particular emphasis on the disadvantaged and vulnerable populations, thereby contributing to sustainable development of the country.
 
The Ministry thereby adopts an open-network collaborative type of governance for the health system based on an inter-sectoral approach and cooperates with other ministries, the private sector and the Civil Society in order to achieve its goals. As emphasized by the Director-General of Health, Professor Walid Ammar, during his address as the Laureat of the renewed Shousha Foundation Prize by the WHO for his significant contribution to public health in Lebanon:

“If I should attribute progress to one single characteristic of the health system, I would say: innovative governance. The most difficult leadership is that of getting things done by a multitude of stakeholders with different agenda, interests, and beliefs. The Lebanese society is plural and diverse by its different confessions and political groups, a strong private-for-profit sector and an active civil society with powerful NGOs. Considering the very limited resources and weak authority of the public sector, the challenge is how to make all these partners work together to achieve national health goals. The answer is to find a non-hierarchical governance structure, that replaces control and command leadership, by a collaborative leadership to achieve common goals through an open networking type of governance”. 

The MOPH promotes partnership with not only governmental entities but also non-governmental entities to achieve national goals through innovative governance mechanisms, such as inter-ministerial collaboration to promote inter-sectoral action, public-private partnership to jointly address national system challenges such a fragmentation of health financing and service provision, partnerships with  academia, including University Hospitals, to strengthen health systems and implementation research in order to further improve health services and ensure alignment of efforts towards achieving national health goals.
    1
    ...
ATC Name B/G Ingredients Dosage Form Price
B02BD02 BERIATE BioHuman Coagulation Factor VIII - 500IU 500IU Injectable lyophilised powder for solution+diluent L.L
J05AF10 HEPCAVIR 1 G Entecavir monohydrate - 1mg 1mg Tablet, film coated L.L
J05AF10 HEPCAVIR 0.5 G Entecavir monohydrate - 0.5mg 0.5mg Tablet, film coated L.L
B06AC05 TAKHZYRO BioTech Lanadelumab - 300mg/2ml 300mg Injectable solution L.L
N05AX13 TREVICTA B Paliperidone - 525mg 525mg Injectable suspension, prolonged release L.L
N05AX13 TREVICTA B Paliperidone - 350mg 350mg Injectable suspension, prolonged release L.L
N05AX13 INVEGA SUSTENNA B Paliperidone palmitate - 150mg 150mg Injectable suspension, prolonged release L.L
N05AX13 INVEGA SUSTENNA B Paliperidone palmitate - 100mg 100mg Injectable suspension, prolonged release L.L
L01XX52 VENCLEXTA B Venetoclax - 10mg week 1, Venetoclax - 50mg week 2, Venetoclax - 100mg week 3&4 Tablet L.L
L04AC05 USTEKIREL BioTech Ustekinumab - 90mg 90mg Injectable solution L.L
L04AX04 LENALIDOMIDE NEAPOLIS G Lenalidomide - 15mg 15mg Capsule L.L
L04AX04 LENALIDOMIDE NEAPOLIS G Lenalidomide - 10mg 10mg Capsule L.L
L01CE02 IRINOTECAN GP PHARM G Irinotecan HCl trihydrate - 100mg/5ml 100mg/5ml Injectable concentrated solution L.L
L01XA03 OXALIPLATIN EBEWE G Oxaliplatin - 50mg/10ml 50mg/10ml Injectable concentrated solution L.L
L01CA04 EBERELBIN G Vinorelbine (tartrate) - 50mg/5ml 50mg/5ml Injectable concentrated solution L.L
L01BC01 ALEXAN G Cytarabine - 1,000mg/20ml 1,000mg/20ml Injectable solution L.L
L01CD02 DOCETAXEL EBEWE G Docetaxel - 80mg/8ml 80mg/8ml Injectable solution L.L
L04AA06 MYFORTIC B Mycophenolic acid (sodium) - 360mg 360mg Tablet, gastroresistant L.L
N03AF01 TEGRETOL B Carbamazepine - 2% 2% Suspension L.L
L01DB01 DOXORUBICINE EBEWE G Doxorubicin HCl - 2mg/ml 50mg/25ml Injectable concentrated solution L.L
L01CE02 IRINOTECAN THYMOORGAN G Irinotecan HCl - 40mg/2ml 40mg/2ml Injectable concentrated solution L.L
L01AA06 HOLOXAN B Ifosfamide - 1g 1g Injectable powder for solution L.L
L01AX03 TEGOZOL G Temozolomide - 250mg 250mg Capsule L.L
L01XA03 OXALIPLATINO GP PHARM G Oxaliplatin - 100mg 100mg Injectable lyophilised powder for solution L.L
L04AA44 RINVOQ B Upadacitinib - 15mg 15mg Tablet, prolonged release L.L
L01CD02 DOCETAXEL ACCORD G Docetaxel - 20mg/ml 20mg/1ml Injectable concentrate for solution L.L
L01DC01 BLEOCIN B Bleomycin (sulfate) - 15U 15U Injectable lyophilised powder for solution L.L
J05AB14 VALGANCICLOVIR ARROW G Valganciclovir (HCl) - 450mg 450mg Tablet, coated L.L
M05BX04 PROLIA BioTech Denosumab - 60mg/ml 60mg/ml Injectable solution L.L
B02BX06 HEMLIBRA BioTech Emicizumab - 150mg/ml 150mg/ml Injectable solution L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026